Reports


Artemisinin Combination Therapy Market, Sector / Industry Report & Analysis, 2018-2025 (Includes Business Impact of COVID-19)

  • TBI717617
  • August 01, 2019
  • Global
  • 132 pages
  • HCCResearch
                                              Abstract, Snapshot, Market Analysis & Market Definition: Global Artemisinin Combination Therapy Market

The artemisinin combination therapy market size was valued at USD 363.8 million in 2017. It is projected to expand at a CAGR of 8.5% during the forecast period. There has been a tremendous upsurge in the demand for artemisinin combination therapy (ACT) over the past few years following its recognition as first line treatment for malaria by the World Health Organization.
ACTs are the most effective antimalarial medicines available today. Currently, WHO recommends 6 ACTs for the treatment of malaria. In recent years, access to them has increased considerably. By 2016, they were adopted as first-line treatment in almost 80 countries. Their benefits include fast action, high efficacy, and reduced possibility of developing resistance.
 
Pipeline for new antimalarial drugs is rising and some of them have been introduced recently. Some of the new ACTs, which are registered and used in some countries, are arterolane-piperaquine, artesunate-pyronaridine, artemisinin-piperaquine base, and artemisinin-napthoquine.
Rising R & D activities and improving medical infrastructure, mainly in developing economies including India and China, are stimulating the growth of the market. Increasing demand from malaria endemic countries such as Uganda, Nigeria, Congo, and other South-East Asian countries is likely to drive the market during the forecast period.
Malaria is one of the most distressing diseases globally with around 250 million new cases reported each year. According to findings of the Medicines Malaria Venture (MMV), in 2016 , of the estimated 445,000 deaths caused by malaria worldwide, 91.0% of them occurred in Africa.
Malaria epidemic is on a rise and climate change is further rendering surroundings conducive for vector mosquitoes to thrive. Around 40.0% of the global population are at risk of infection and while over 90.0% of cases occur in Africa, the new frontier of the disease is South East Asia, where 83.0% of the population (over 1.3 billion people) are at risk. According to WHO, together with tuberculosis and HIV, malaria is one of the most prevalent diseases in Africa and the leading cause of death in children under 5-year-old.
Malaria during pregnancy poses a significant amount of health risk to unborn child and mother. It can lead to severe outcomes, such as anemia, low infant birth weight, and abortion. Several studies to evaluate safety and efficacy of ACTs in pregnant women have been conducted. According to a study conducted by Novartis in collaboration with WHO, it was found that exposure to artemether-lumefantrine in pregnancy is not related with specific health risks in terms of malformations, perinatal mortality, or developmental impairment.

Market Segmentation, Outlook & Viewpoint: Global Artemisinin Combination Therapy Market


Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2025)

Artemether+Lumefantrine

Artesunate+Amodiaquine

Dihydroartemisinin+Piperaquine

Artesunate+Mefloquine

Artesunate+Sulfadoxine-Pyrimethamine

Pyronaridine-Artesunate


Key Players, Recent Developments & Regional Insights: Global Artemisinin Combination Therapy Market


There are currently 6 ACTs available, which are artemether+lumefantrine (AL), artesunate+amodiaquine, artesunate+mefloquine (AS+MQ), Dihydroartemisinin+piperaquine (DHA PPQ), artesunate+sulfadoxine-pyrimethamine (AS+SP), and pyronaridine-artesunate (PA). AL was the largest segment in 2017.
 
It was the first ACT to be launched and prequalified by WHO for its efficacy, safety, and quality. It is available in more than 60 countries and is the only ACT approved by the U.S. FDA. On the other hand, DHA PPQ is estimated to be the fastest growing segment during the forecast period.

Regional Insights
The Middle East and Africa held the largest share in the artemisinin combination therapy market in 2017. Presence of large production base of artemisinin herbs and rising demand in malaria endemic countries are contributing to the growth of the market in MEA and Asia Pacific. Though African countries, where the incidence of malaria is the highest, have increased malaria control strategies, effective treatment and control, but it still presents a huge logistical difficulty. As several at-risk people live in extreme poverty in remote areas, WHO and other organizations are working on completely eradicating it in Africa and thus, over the coming years, the adoption rate of ACT is further expected to increase.
Artemisinin Combination Therapy Market Share Insights
Some of the major players in the market are Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca Laboratories, Guilin Pharmaceuticals, and KPC Pharmaceuticals.Major players are engaging in different marketing strategies such as increasing geographic presence, R & D, new product development, and indication extension.

Key Insights Covered: Global Artemisinin Combination Therapy Market
1.  North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Artemisinin Combination Therapy industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Artemisinin Combination Therapy industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Artemisinin Combination Therapy industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Artemisinin Combination Therapy industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Artemisinin Combination Therapy industry.

Research Methodology: Global Artemisinin Combination Therapy Market
  • Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  • Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  • Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other

Table of Contents
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
    1.1.1 Purchased database:
    1.1.2 HCC's internal database
1.2 Research Methodology
1.3 Geographic Scope & Assumptions
1.4 Region-wise Market Calculation
    1.4.1 Region-wise market: Base estimates
    1.4.2 Global market: CAGR calculation
1.5 Region-based Segment Share Calculation
1.6 List of Secondary SourcesChapter 2 Executive Summary
2.1 Market SnapshotChapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
    3.2.1 Rising Demand for Artemisinin Combinat
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form